(VIANEWS) – The NASDAQ ended the session with Pacific Biosciences of California (PACB) jumping 19.84% to $9.99 on Thursday while NASDAQ rose 7.35% to $11,114.15.
Pacific Biosciences of California’s last close was $8.34, 72.14% under its 52-week high of $29.94.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Earnings per Share
Pacific Biosciences of California’s trailing 12 months EPS is $-0.34.
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -34.53%.
Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 134.69M for the twelve trailing months.
Pacific Biosciences of California’s worth is way higher than its 50-day moving average of $6.50 and way above its 200-day moving average of $7.21.
Today’s last reported volume for Pacific Biosciences of California is 10030100 which is 30.28% above its average volume of 7698850.
Yearly Top and Bottom Value
Pacific Biosciences of California’s stock is valued at $9.99 at 21:10 EST, way under its 52-week high of $29.94 and way higher than its 52-week low of $3.85.
More news about Pacific Biosciences of California (PACB).